Deepson Bio Receives Presidential Award at 2025 Korea Invention Patent Exhibition
Award highlights promise of ultrasound-based innovation in addressing unmet needs in dementia treatment SEOUL, South Korea, Jan. 12, 2026 /PRNewswire/ -- Deepson Bio Co., Ltd., a medical technology company focused on ultrasound-based approaches to dementia treatment, was honored with the Presidential Award, the highest recognition presented at the event, at the 2025 Korea Invention Patent Exhibition held at...
LumiMind Wins SPEED AWARD at CES 2026 for Innovative Non-Invasive Sleep Technology With Real-Time EEG
LAS VEGAS, Jan. 12, 2026 /PRNewswire/ -- LumiMind, a next-generation neurotechnology company advancing non-invasive brain health solutions, today announced that it has won the SPEED AWARD at CES 2026 for its breakthrough consumer sleep technology, LumiSleep. The SPEED AWARD is a prestigious global honor recognizing groundbreaking technological advancements across AI, neurotechnology, and...
Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease
CAMBRIDGE, Mass., Jan. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage, generative AI-driven drug discovery company, today announced the completion of first patient first dose in BETHESDA: a Phase IIa clinical trial of ISM5411 (NCT07265570), which has recently been granted the generic name of Garutadustat by the United States Adopted Names (USAN) Council. Garutadustat (originally ISM5411) is a...
WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing
SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of PatroLabTM, a state-of-the-art digital twin platform designed to transform bioprocess development and manufacturing. By combining advanced real-time process monitoring with Raman-based Process Analytical Technology (PAT) and predictive in-silico modeling, PatroLab™ enables real-time and smarter analytics, proactive...
CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors
SHANGHAI, PHILADELPHIA and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, and Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical collaboration to conduct a...
Major global health grant awarded to Oktopi to accelerate equitable medicine development capability worldwide.
MELBOURNE, Australia, Jan. 12, 2026 /PRNewswire/ -- Oktopi has been awarded a significant grant from the Gates Foundation to advance global access to high-quality medicine development expertise, with a particular focus on supporting innovators in low- and middle-income countries (LMICs). This funding will enable Oktopi to build and expand its AI-informed knowledge and workflow engine, bringing best-practice to the...
BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions
Reshaping the Global Drug Development Landscape with the Industry's Only Natively AI-Powered Omnimodal Foundation Model for Tumor and Immune Biology SAN ANTONIO, Jan. 12, 2026 /PRNewswire/ -- Frost & Sullivan is pleased to announce that BostonGene has been recognized for 2025 Global Technology Innovation Leadership in the AI-driven Precision Oncology Solutions sector for its outstanding achievements in Technology Innovation Leadership. This recognition...
Leadgene Biosolutions Expands Its Product Portfolio Following Strategic Integration, Advancing Early-Stage Mixing and Long-Term Metabolic Insight
TAIPEI, Jan. 12, 2026 /PRNewswire/ -- Leadgene Biosolutions today announces the expansion of its product portfolio following its strategic integration into Leadgene Biomedical. The expanded portfolio supports both early-stage cell line development and long-term metabolic research, enabling researchers to make more informed decisions earlier in their workflows. Early-Stage Cell Line Development with Defined Mixing and Real-Time Insight For biopharmaceutical...
Haisco Grants Global Rights of Innovative Drug HSK39004 to AirNexis in Deal Exceeding USD 1 Billion
HSK39004, a novel dual‑target therapy, aims to compete in the global COPD market, highlighting innovation and international capabilities BEIJING, Jan. 12, 2026 /PRNewswire/ -- On January 9, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with US based biotech AirNexis. Under the agreement, Haisco grants AirNexis the rights to develop,...
Novo Nordisk’s GLP‑1 RA–A Modern Treatment for Obesity Management–is Linked to Lower Household Spending on Alcohol and Tobacco
Real-world data analysis suggests that families with at least one member using Novo Nordisk's GLP‑1 RA for weight management tend to reduce spending on alcohol and cigarettes. JAKARTA, Indonesia, Jan. 12, 2026 /PRNewswire/ -- At the international scientific congress ObesityWeek® held late last year in Atlanta, United States, Novo Nordisk presented findings from a real-world analysis of grocery spending data...
